| Ytd | -14.44% | |
| 1y | 20.52% |
| Open | 6.67 | Prev Close | 6.67 | Low | 6.33 | High | 6.86 | Mkt Cap | 426.83M |
| Vol | 370.70K | Avg Vol | 371.60K | EPS | -1.02 | P/E | N/A | Forward P/E | N/A |
| Beta | 1.23 | Short Ratio | 27.74 | Inst. Own | 12.85% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 11-03 | 50-d Avg | 6.60 | 200-d Avg | 7.12 | 1yr Est | 0.00 |
EPRX News
The number of patients experiencing moderate to severe odynophagia (pain swallowing) in the cohorts
Eupraxia Pharmaceuticals (NASDAQ:EPRX) reported quarterly losses of $(0.23) per share which met the
New data presented at Digestive Disease Week (DDW) demonstrating improvement of fibrosis and inflamm
The consensus price target hints at a 145.4% upside potential for Eupraxia Pharmaceuticals Inc. (EPR
Shares of Eupraxia Pharmaceuticals Inc. (NASDAQ: EPRX - Get Free Report) have received an average ra
VANCOUVER, British Columbia, July 13, 2026 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. (“Eupra
VANCOUVER, British Columbia, July 07, 2026 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. ("Eupra
Oppenheimer analyst Jay Olson initiates coverage on Eupraxia Pharmaceuticals (NASDAQ:EPRX) with a
VANCOUVER, British Columbia, June 19, 2026 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. (“Eupra
VANCOUVER, British Columbia, May 28, 2026 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. ("Euprax
US stock futures up, VNET Group shares down 3.8% after reporting Q1 loss of $(1.20) per share on $39
Gainers: PHGE +97.3%, ARTL +74.8%, QTEX +52.4%, MNTX +34.4%, HLIT +28.3%, WOK +25%, CPSH +24.7%, COD
Top analysts changed outlook on top names. See all rating changes at benzinga.com/analyst-stock-rati
Stifel analyst Annabel Samimy initiates coverage on Eupraxia Pharmaceuticals (NASDAQ:EPRX) with a
Eupraxia Pharmaceuticals (NASDAQ:EPRX) reported quarterly losses of $(0.23) per share which missed t
Robust response in highest dose cohort after 36 weeks following a single treatment of EP-104GI Compl
EoEHSS (EoE Histology Scoring System) is a standardized method used to monitor esophageal tissue dam
Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (NASDAQ:EPRX) (TSX:EPRX)
EREFS is a standardized visual scoring system that gastroenterologists use when performing an endosc
HC Wainwright & Co. analyst Brandon Folkes reiterates Eupraxia Pharmaceuticals (NASDAQ:EPRX)
VANCOUVER, British Columbia, May 01, 2026 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. ("Euprax
HC Wainwright & Co. analyst Brandon Folkes reiterates Eupraxia Pharmaceuticals (NASDAQ:EPRX)
VANCOUVER, British Columbia, April 22, 2026 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. ("Eupr
This is the first release of 36-week symptom response & tissue health data for the highest dose
ACCO, CDE and EPRX have been added to the Zacks Rank #5 (Strong Sell) List on April 2nd, 2026.
William Blair on Monday initiated coverage on Eupraxia Pharmaceuticals Inc. (NASDAQ: EPRX), a clinic
William Blair starts Eupraxia at Outperform as the analyst flags unmet need and sizable market poten
Wall Street analysts changed outlook on top names: Morgan Stanley raised Lemonade's PT to $85,
Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (NASDAQ:EPRX) (TSX:EPRX)
HC Wainwright & Co. analyst Brandon Folkes maintains Eupraxia Pharmaceuticals (NASDAQ:EPRX) w
Ally Bridge Group NY LLC bought a new position in Eupraxia Pharmaceuticals Inc. (NASDAQ: EPRX) in th
Eupraxia Pharmaceuticals (NASDAQ:EPRX) reported quarterly losses of $(0.37) per share which missed t
VICTORIA, British Columbia, March 12, 2026 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. (“Eupra
VICTORIA, British Columbia, Feb. 20, 2026 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. (“Euprax
VICTORIA, British Columbia, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. (“Euprax
Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (NASDAQ:EPRX) (TSX:EPRX)
VICTORIA, British Columbia, Feb. 18, 2026 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. (“Euprax
Cantor Fitzgerald analyst Kristen Kluska maintains Eupraxia Pharmaceuticals (NASDAQ:EPRX) with a
HC Wainwright & Co. analyst Brandon Folkes reiterates Eupraxia Pharmaceuticals (NASDAQ:EPRX)
Eupraxia Pharmaceuticals reported new trial data showing EP-104GI improved esophagus tissue health a
At week 12, the highest dosed patients achieved the best tissue response seen in the trial to date,
The 52-week symptom data reported for Cohort 6 patients is consistent with the long-term durability
Eupraxia's Cohort 9 RESOLVE trial data showed durable remission, improved tissue health, and str
Gainers SciSparc (NASDAQ: SPRC) shares increased by 28.2% to $5.68 during Monday's after-market
Clinical data was reported for the first time in patients receiving an 8 mg dose per injection (Coho